ATE251613T1 - Pyrimidinonderivate zur behandlung von atheroscleros - Google Patents

Pyrimidinonderivate zur behandlung von atheroscleros

Info

Publication number
ATE251613T1
ATE251613T1 AT99942894T AT99942894T ATE251613T1 AT E251613 T1 ATE251613 T1 AT E251613T1 AT 99942894 T AT99942894 T AT 99942894T AT 99942894 T AT99942894 T AT 99942894T AT E251613 T1 ATE251613 T1 AT E251613T1
Authority
AT
Austria
Prior art keywords
group
bond
formula
ring system
conh
Prior art date
Application number
AT99942894T
Other languages
English (en)
Inventor
Colin Andrew Leach
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818375.9A external-priority patent/GB9818375D0/en
Priority claimed from GBGB9902009.1A external-priority patent/GB9902009D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE251613T1 publication Critical patent/ATE251613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99942894T 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros ATE251613T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9818375.9A GB9818375D0 (en) 1998-08-21 1998-08-21 Novel compounds
GBGB9902009.1A GB9902009D0 (en) 1999-01-29 1999-01-29 Novel compounds
PCT/EP1999/006093 WO2000010980A1 (en) 1998-08-21 1999-08-18 Pyrimidinone derivatives for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE251613T1 true ATE251613T1 (de) 2003-10-15

Family

ID=26314252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942894T ATE251613T1 (de) 1998-08-21 1999-08-18 Pyrimidinonderivate zur behandlung von atheroscleros

Country Status (6)

Country Link
US (1) US6559155B1 (de)
EP (1) EP1105377B1 (de)
JP (1) JP2002523402A (de)
AT (1) ATE251613T1 (de)
DE (1) DE69911980T2 (de)
WO (1) WO2000010980A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125883B1 (en) 1999-04-13 2006-10-24 Abbott Gmbh & Co. Kg Integrin receptor ligands
GB9910079D0 (en) * 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
MXPA01011186A (es) * 1999-05-01 2002-08-12 Smithkline Beecham Plc Compuestos de pirimidinona.
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
NZ520752A (en) * 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
FR2815345B1 (fr) * 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
CN101687009A (zh) 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
EP2977452A3 (de) 2007-05-11 2016-05-25 Thomas Jefferson University Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen und störungen
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
CN103827118B (zh) * 2011-07-27 2016-03-09 葛兰素集团有限公司 双环嘧啶酮化合物
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
EP2736908A1 (de) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclische pyrimidonverbindungen
BR112015017397A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos pirimidona bicíclica como inibidores de lp-pla2
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2024196698A2 (en) * 2023-03-17 2024-09-26 Curadh Mtr Compounds and constructs useful for targeting fibroblast activation protein
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145546A (en) * 1975-10-02 1979-03-20 Smith Kline & French Laboratories Limited 4-Pyrimidone compounds
US4154834A (en) * 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
JP2001522844A (ja) 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物

Also Published As

Publication number Publication date
WO2000010980A1 (en) 2000-03-02
US6559155B1 (en) 2003-05-06
JP2002523402A (ja) 2002-07-30
DE69911980D1 (de) 2003-11-13
EP1105377A1 (de) 2001-06-13
DE69911980T2 (de) 2004-09-09
EP1105377B1 (de) 2003-10-08

Similar Documents

Publication Publication Date Title
ATE251613T1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
TR200201413T2 (tr) Faktör Xa' nın inhibitörleri.
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE86247T1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
BG105112A (bg) Средство с антидепресивно действие
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
BR0010220A (pt) Compostos de pirimidinona
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
MX9800146A (es) Nuevos inhibidores de trombina, su preparacion y su uso.
ATE323686T1 (de) Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel
EP1318811A4 (de) Cyclopentylmodulatoren der chemokin-rezeptor-aktivität
TR199802536T2 (xx) Yeni amino asit t�revleri,trombin inhibit�rleri olarak kullan�lmalar�.
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
DE69815311D1 (de) Substituierte derivate von benzosulphonamiden als hemmer des enzym cyclooxygenase ii
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
FR2763949B1 (fr) Compose stabilisant, composition le contenant et procede l'utilisant
EP1422225A4 (de) Benzoisoselenazolderivate mit entzündungshemmender, antiviraler und antithrombotischer wirkung und deren verwendungen
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE277031T1 (de) Dihydrobenzofuranderivate verwendbar als entzündungshemmende mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties